- Home
- SSSS vs COYA Comparison
SSSS vs COYA Comparison
Compare SSSS & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- COYA
- Stock Information
- Founded
- SSSS 2010
- COYA 2020
- Country
- SSSS United States
- COYA United States
- Employees
- SSSS N/A
- COYA N/A
- Industry
- SSSS Finance: Consumer Services
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- SSSS Finance
- COYA Health Care
- Exchange
- SSSS Nasdaq
- COYA Nasdaq
- Market Cap
- SSSS 108.1M
- COYA 108.4M
- IPO Year
- SSSS N/A
- COYA 2022
- Fundamental
- Price
- SSSS $4.48
- COYA $5.26
- Analyst Decision
- SSSS Buy
- COYA Strong Buy
- Analyst Count
- SSSS 2
- COYA 4
- Target Price
- SSSS $8.00
- COYA $17.00
- AVG Volume (30 Days)
- SSSS 156.0K
- COYA 66.8K
- Earning Date
- SSSS 05-07-2025
- COYA 05-08-2025
- Dividend Yield
- SSSS N/A
- COYA N/A
- EPS Growth
- SSSS N/A
- COYA N/A
- EPS
- SSSS N/A
- COYA N/A
- Revenue
- SSSS $4,673,427.00
- COYA $3,554,061.00
- Revenue This Year
- SSSS $6.95
- COYA $94.45
- Revenue Next Year
- SSSS N/A
- COYA N/A
- P/E Ratio
- SSSS N/A
- COYA N/A
- Revenue Growth
- SSSS N/A
- COYA N/A
- 52 Week Low
- SSSS $3.52
- COYA $4.65
- 52 Week High
- SSSS $6.83
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- SSSS 37.20
- COYA 40.06
- Support Level
- SSSS $4.29
- COYA $5.08
- Resistance Level
- SSSS $4.74
- COYA $5.60
- Average True Range (ATR)
- SSSS 0.34
- COYA 0.54
- MACD
- SSSS -0.02
- COYA -0.05
- Stochastic Oscillator
- SSSS 23.08
- COYA 29.47
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.